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Abstract
Background: A definitive conclusion on the efficacy of mesenchymal stromal cells-derived conditioned medium (MSCs-CM) in 
pulmonary fibrosis has not yet been reached. Therefore, the present meta-analysis intends to investigate the efficacy of MSCs-CM 
administration on improvement of pulmonary fibrosis.
Methods: An extensive search was performed on the Medline, Embase, Scopus and Web of Science databases by the end of August 
2019. Outcomes in the present study included pulmonary fibrosis score, lung collagen deposition, lung collagen expression, 
transforming growth factor β1 (TGF-β1) expression and interleukin-6 expression. Finally, the data were pooled and an overall 
standardized mean difference (SMD) with a 95% confidence interval (CI) was reported.
Results: Data from seven studies were included. Analyses showed that administration of MSCs-CM significantly improved 
pulmonary fibrosis (SMD = -2.36; 95% CI: -3.21, -1.51). MSCs-CM administration also attenuated lung collagen deposition (SMD 
= -1.70; 95% CI: -2.18, -1.23) and decreased expression of type I collagen (SMD = -6.27; 95% CI: -11.00, -1.55), type III collagen 
(SMD = -5.16; 95% CI: -9.86, -0.47), TGF- β1 (SMD = -3.36; 95% CI: - 5.62, -1.09) and interleukin-6 (SMD = -1.69; 95% CI: - 
3.14, -0.24).
Conclusion: The present meta-analysis showed that administration of MSCs-CM improves pulmonary fibrosis. It seems that the 
effect of MSCs-CM was mediated by reducing collagen deposition as well as inhibiting the production of inflammatory chemokines 
such as TGF-β1 and interleukin 6 (IL-6). Since there is no evidence on the efficacy of MSCs-CM in large animals, further studies 
are needed to translate the finding to clinical studies.
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Idiopathic pulmonary fibrosis is a chronic and progressive 
disease with an unknown etiology. The prevalence and 
incidence of idiopathic pulmonary fibrosis have been 
increasing in recent decades1 and it accounts for about 
20% of all interstitial lung diseases.2 About 3 million 
people have been reported worldwide to have idiopathic 
pulmonary fibrosis, with its prevalence increasing with 
age.3
There is not a definitive treatment for pulmonary 
fibrosis. Initial studies have suggested the positive effects 
of corticosteroids and immunosuppressive agents in 
management of pulmonary fibrosis. However, systematic 
reviews have shown that there is insufficient evidence for 
the efficacy of these therapies.4,5 The current guidelines 
approve pirfenidone and nintedanib for treatment of 
pulmonary fibrosis. However, the ideal therapeutic 
approach for management of pulmonary fibrosis is still 
under investigation.6,7
Stem cells transplantation has been suggested as a 
therapeutic option for many conditions.8-10 A systematic 
review in 2015 showed that administration of mesenchymal 
stromal cells (MSCs) in animal models of pulmonary 
fibrosis improved fibrosis, decreased collagen deposition 
in lung, and reduced the expression of profibrotic 
chemokines.11 Although preclinical studies have shown 
the benefit of MSCs transplantation, this treatment 
option has some limitations, including the possibility 
of tumorigenesis. In addition, circulating MSCs play a 
critical role in the pathogenesis of pulmonary fibrosis. For 
example, bone marrow-derived mesenchymal progenitor 
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conversion to myofibroblasts is intensified in the presence 
of tumor growth factor β (TGF-β), which is elevated in 
pulmonary fibrosis.12 On  the other hands, lung resident 
MSCs secretome has anti-fibrotic effects.13 Therefore, 
caution should be exercised in the administration of MSCs 
to attenuate the progression of pulmonary fibrosis.
The use of conditioned medium as an alternative option 
to stem cell therapy has been suggested in some studies.14,15 
Recent studies show that the paracrine effects of MSCs 
play a major role in treatment of acute and chronic 
conditions.16-18 Therefore, administration of MSCs-
derived conditioned medium (MSCs-CM) may have all 
the effects of stem cell transplantation while omitting the 
side effects of stem cell administration. Preclinical studies 
have shown that administration of MSCs-CM could 
improve pulmonary fibrosis;19-21 however, no consensus 
has yet been made in this field. Therefore, the present 
systematic review and meta-analysis intends to investigate 
the efficacy of MSCs-CM administration in improving 
pulmonary fibrosis.
Materials and Methods
Study Design and Search Strategy
An extensive search of the Medline, Embase, Scopus and 
Web of Science databases was conducted by the end of 
August 2019. PICO in the present study was defined as 
pulmonary fibrosis (problem), administration of MSCs-
CM (intervention), comparison with non-treated animals 
(comparison), and pulmonary fibrosis score and fibrotic 
and profibrotic markers (outcome), respectively.
Keywords related to “pulmonary fibrosis” in combination 
with words related to “mesenchymal stem cell derived 
conditioned medium” were used in the search databases. 
Systematic searches were performed for each database 
using proper Boolean operators and standard tags. The 
search query in Medline (via PubMed) is presented in 
Appendix 1. In addition, a manual search was conducted 
on Google, Google Scholar and bibliography of relevant 
articles to find additional studies.
Eligibility Criteria
We investigated all original studies published/accepted 
in a peer-reviewed journal on the efficacy of MSCs-CM 
administration in managing pulmonary fibrosis in animal 
models. There was no time or language limitation for the 
search. Exclusion criteria included lack of an untreated 
control group, conditioned medium derived from non-
MSCs, MSCs-derived secretome, genetically engineered 
MSCs-CM, in vitro studies and review articles.
Data Gathering and Synthesis
Records obtained from the systematic search were screened 
by two independent reviewers. Potential relevant studies 
were then studied in full details and relevant articles were 
saved. Data were recorded by two researchers independently 
in a pre-designed checklist. These data included first 
author’s name, year of publication, number of animals, 
species, gender and age of animal, pulmonary fibrosis 
induction model, interval time between pulmonary fibrosis 
induction to treatment, source of MSCs, administration 
route, administered volume, type of graft (xenograft or 
allograft), follow-up duration and assessed outcome. Data 
were recorded as mean and standard deviation. Since in 
most animal studies, data are presented in graphs using 
plot digitizer software, mean and standard deviation were 
extracted. The use of this technique is a common method 
in animal meta-analysis studies.22-25
Outcome
First, we aimed to evaluate the effect of MSCs-CM on 
pulmonary fibrosis score, lung collagen deposition, 
collagen subtypes expression, TGF-β1 expression and 
other profibrotic chemokines. Since meta-analysis should 
be performed when the outcome has been reported in at 
least two studies, we had to assess pulmonary fibrosis score, 
lung collagen deposition, type I collagen, type III collagen, 
TGF-β1 expression and interleukin 6 (IL-6) expression.
Risk of Bias Assessment
Quality control of articles was performed based on 
SYRCLE’s risk of bias tool – a 10-item risk assessment tool 
for pre-clinical studies.26
Statistical Analysis
Data were analyzed using STATA 14.0 statistical software. 
Mean and standard deviation of the outcomes were 
recorded and a pooled effect size with a 95% confidence 
interval (CI) was reported for each study based on 
standardized mean difference (SMD) calculation. I2 
was used for assessment of heterogeneity and Egger’s 
test for publication bias. Finally, subgroup analysis and 
meta-regression were performed to find the source of 
heterogeneity and to find the factors affecting the efficacy 
of MSCs-CM on the improvement of pulmonary fibrosis. 




Finally, 274 non-repetitive records were screened and data 
from 7 studies 19,21,27-31 were included in the meta-analysis 
(Figure 1). Four studies were performed on rats while three 
were conducted on mice. Four studies used a bleomycin-
induced pulmonary fibrosis model while three studies used 
other models such as silica-induced and radiation-induced 
pulmonary fibrosis. The time interval between pulmonary 
fibrosis induction to MSCs-CM administration ranged 
from 0 to 28 days. Four studies performed MSCs-CM 
transplantation within the first 24 hours after pulmonary 
fibrosis induction. The type of MSCs used was bone 
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marrow-derived mesenchymal stromal cells (BMMSCs) 
in three studies, adipose tissue-derived mesenchymal 
stromal cells (ADSCs) in two studies, and amniotic-
derived mesenchymal tissue cells (AMSCs) in two studies. 
MSCs-CM was injected intravenously in five studies and 
in situ in two studies. The transplanted volume of MSCs-
CM ranged from 10 μL to 1000 μL. Follow-up duration 
varied between 11 and 28 days. Six studies examined 
fibrosis score, seven studies examined collagen deposition 
in lung tissue, four studies examined the expression of type 
I collagen, three studies type III collagen, three studies 
TGF-β1 expression and three studies IL-6 expression in 
lung tissue. Table 1 illustrates the characteristics of the 
included studies.
Risk of Bias Assessment
SYRCLE’s risk of bias tool showed random sequence 
generation, baseline characteristics of included animals, 
random housing, random outcome assessment, selective 
reporting, and other sources of bias in all eligible studies 
were of low risk. However, the risk of bias of allocation 
concealment and blinding of trial caregiver was unclear 
in six studies. Blinding of outcome assessment and 
incomplete outcome data in one study had high risk of 
bias (Table 2 and Figure 2A).
Publication Bias
The findings presented in Figures 2B and G show that 
according to Egger’s test, there was no publication 
bias in pulmonary fibrosis score (coefficient = 2.45; P 
= 0.081), collagen deposition (coefficient = 2.36; P = 
0.315), expression of type I collagen (coefficient = 1.82; 
P = 0.495), type III collagen (coefficient = 12.17; P = 
0.620), TGF-β1 (coefficient = 5.31; P = 0.198) and IL-6 
(coefficient = 0.61; P = 0.919). 
Meta-analysis: Efficacy of MSCs-CM on Pulmonary 
Fibrosis Score
Five studies reported the efficacy of MSCs-CM on 
pulmonary fibrosis score. Meta-analysis of this section 
showed that administration of MSCs-CM significantly 
reduced the score of pulmonary fibrosis. In other words, 
administration of MSCs-CM improves pulmonary fibrosis 
(SMD = -2.36; 95% CI: -3.21 to -1.51; P < 0.0001) 
(Figure 3A). Subgroup analysis and meta-regression were 
performed despite mild heterogeneity between studies (I2 
= 52.0%; P = 0.064) (Table 3 and Figure 4).
Subgroup analysis indicated that the possible source of 
heterogeneity was animal species, type of MSCs and route 
of administration of MSCs-CM. It is worth noting that 
in all conditions, administration of MSCs-CM improved 
pulmonary fibrosis (P < 0.001) (Table 3).
Meta-regression also showed that none of the time 
interval between pulmonary fibrosis induction to MSCs-
CM administration (P = 0.722), administered MSCs-CM 
volume (P = 0.160), number of MSCs for conditioned 
medium derivation (P = 0.754) and follow-up duration (P 
= 0.920) had any effect on the efficacy of MSCs-CM on 
pulmonary fibrosis score (Figure 4).
Meta-analysis: Efficacy of MSCs-CM on Lung Collagen 
Deposition
Six studies reported the efficacy of MSCs-CM on reduction 
of collagen deposition. Meta-analysis of this section 
Figure 1. PRISMA Flow Diagram of Present Meta-analysis.
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showed that administration of MSCs-CM significantly 
decreased collagen deposition in animals with pulmonary 
fibrosis (SMD = -1.70; 95% CI: -2.18 to -1.23; P < 
0.0001) (Figure 3B).
Subgroup analysis showed that differences in animal 
species, pulmonary fibrosis induction model, type of 
MSCs, type of MSCs-CM administration, and type 
of graft (xenograft versus allograft) did not affect the 
efficacy of MSCs-CM in reducing collagen deposition in 
pulmonary fibrosis (Table 3).













Random sequence generation + + + + + + +
Baseline characteristics + + + + + + +
Allocation concealment ? ? ? ? ? + ?
Random housing + + + + + + +
Blinding of trial caregiver ? ? ? ? ? + ?
Random outcome assessment + + + + + + +
Blinding of outcome assessment + + + ? - + -
Incomplete outcome data - + + + + + +
Selective reporting + + + + + + +
Other source of bias + + + + + + +
+, Low risk of bias; -, High risk of bias; ?, Unclear risk of bias.
Figure 2. Assessment of Risk of Bias. A) publication bias of mesenchymal stromal cells derived conditioned medium on lung fibrosis score. B) lung tissue 
collagen deposition. C) lung tissue collagen type-I. D) and collagen type-III. E) expression, lung tissue transforming growth factor β1 (TGF-β1). F) and interleukin 
6 expression. G) in lung fibrosis animal models.
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Meta-regression also showed that none of the time 
interval factors between pulmonary fibrosis induction 
to MSCs-CM administration (P = 0.528), administered 
MSCs-CM volume (P = 0.814), and number of MSCs 
for conditioned medium derivation (P = 0.58) as well 
as follow-up duration (P = 0.867) had any effect on the 
efficacy of MSCs-CM on reducing collagen deposition in 
the lung (Figure 5).
Meta-analysis: Efficacy of MSCs-CM on Type I Collagen 
and Type III Collagen Expression
Data from four and three experiments were entered to 
evaluate the efficacy of MSCs-CM on type I collagen and 
type III collagen expression, respectively. Analyses showed 
that administration of MSCs-CM decreased the expression 
of type I collagen (SMD = -6.27; 95% CI: -11.00 to -1.55; 
P = 0.009) and type III collagen (SMD = -5.16; 95% CI: 
-9.86 to -0.47; P = 0.031) after induction of pulmonary 
fibrosis (Figures 3C and D).
Meta-analysis: Efficacy of MSCs-CM on Lung TGF-β1 
and IL-6 Expression
Analyses on data from three studies showed that 
administration of MSCs-CM significantly reduced 
TGF-β1 (SMD = -3.36; 95% CI: - 5.62 to -1.09; P = 
0.004) and IL-6 (SMD = -1.69; 95% CI: - 3.14 to -0.24; 
P = 0.022) expression in lung tissue following pulmonary 
fibrosis (Figures 3E and F).
Discussion
The present meta-analysis for the first time collected and 
analyzed quantitative data on the effect of MSCs-CM on 
the pulmonary fibrosis in animal studies. Analyses showed 
that administration of MSCs-CM improved pulmonary 
fibrosis. The effect of MSCs-CM could be mediated by 
reducing collagen deposition and expression as well as 
inhibiting the production of inflammatory chemokines 
such as TGF-β1 and IL-6.
Risk of bias was low in most studies, which was one of the 
strengths of the present meta-analysis. However, blinding 
Figure 3. Forest Plots for the Effect of Mesenchymal Stromal Cells Derived Conditioned Medium on Lung Fibrosis Score. A) lung tissue collagen deposition. B) 
lung tissue collagen type-I. C) and collagen type-III. D) expression, lung tissue transforming growth factor β1 (TGF-β1). E) and interleukin 6 expression. F) in lung 
fibrosis animal models.
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Figure 4. Meta-regression for the Effect of Time Interval between Lung Fibrosis Inductions to Mesenchymal Stromal Cells Derived Conditioned Medium (MSCs-
CM) Administration. A) administrated MSCs-CM volume. B) number of MSCs for derivation of conditioned medium. C) and follow up duration. D) on the effect 
of MSCs-CM on lung fibrosis score.
Figure 5. Meta-regression for the effect of Time Interval between Lung Fibrosis Inductions to Mesenchymal Stromal Cells Derived Conditioned Medium (MSCs-
CM) Administration. A) administrated MSCs-CM volume. B) number of MSCs for derivation of conditioned medium. C) and follow up duration. D) on the effect 
of MSCs-CM on collagen deposition after lung fibrosis induction.
of trial caregiver and allocation concealment details were 
not reported in six articles. Since the assessed outcome 
in the present study are histopathology assessment and 
protein expression assay, the blinding status seems to have 
little impact on the reported findings. 
The reduction of fibrosis in the present study was 
evaluated by summarizing the data presented based 
on fibrosis score. This technique is a standard method 
for examining the rate of tissue fibrosis in the lung.32,33 
However, in interpreting the findings, the blinding status 
of outcome assessor is important. In the five studies 
included in this section, the risk of bias in the assessment 
of fibrosis score was low in four studies and unclear in one. 
Therefore, the findings are reliable.
Subgroup analysis showed that differences in the sources 
of MSCs did not affect the efficacy of MSCs-CM in 
improving fibrosis and collagen deposition. This finding 
is important because access to ADSCs cells is much easier 
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Table 3. Subgroup Analysis for Assessment of MSCs-CM Effect on Fibrosis Score and Collagen Deposition in Lung Fibrosis Animal Models
Subgroup Number of Experiments SMD (95% CI) P Value Heterogeneity P Value
Fibrosis score
Pooled analysis 6 -2.36 (-3.21 to -1.50) <0.0001 52.0% 0.064
Animal species
Mice 2 -1.98 (-2.96 to -0.99) <0.0001 20.4% 0.262
Rat 4 -2.36 (-3.21 to -1.50) <0.0001 63.8% 0.040
LF induction model
Bleomycin 5 -2.39 (-3.44 to -1.36) <0.0001 61.5% 0.034
Silica NA NA NA NA NA
Type of MSCs
AMSCs 2 -1.98 (-2.96 to -0.99) <0.0001 20.4% 0.262
ADSCs 3 -2.67 (-4.53 to -0.81) 0.005 75.7% 0.016
BMMSCs 1 NA NA NA NA
Route of administration
In situ 2 -1.98 (-2.96 to -0.99) <0.0001 20.4% 0.262
IV 4 -2.56 (-3.86 to -1.26) <0.0001 63.8% 0.040
Type of graft
Xenograft 3 -2.94 (-4.75 to -1.13) 0.001 78.4% 0.010
Allograft 3 -1.91 (-2.78 to -1.04) <0.0001 0.0% 0.808
Collagen deposition
Pooled analysis 7 -1.70 (-2.18 to -1.23) <0.0001 0.0% 0.797
Animal species
Mice 3 -1.53 (-2.16 to -0.90) <0.0001 0.0% 0.705
Rat 4 -1.92 (-2.64 to -1.21) <0.0001 0.0% 0.628
LF induction model
Bleomycin 4 -1.73 (-2.36 to -1.09) <0.0001 0.0% 0.418
Other 3 -1.67 (-2.39 to -0.95) <0.0001 0.0% 0.883
Type of MSCs
AMSCs 2 -1.49 (-2.23 to -0.75) <0.0001 0.0% 0.418
ADSCs 2 -2.37 (-3.58 to -1.15) <0.0001 0.0% 0.398
BMMSCs 3 -1.67 (-2.39 to -0.95) <0.0001 0.0% 0.883
Route of administration
In situ 2 -1.49 (-2.23 to -0.75) <0.0001 0.0% 0.418
IV 5 -1.85 (-2.47 to -1.24) <0.0001 0.0% 0.756
Type of graft
Xenograft 2 -1.49 (-2.23 to -0.75) <0.0001 0.0% 0.418
Allograft 5 -1.85 (-2.47 to -1.24) <0.0001 0.0% 0.756
ADSCs, Adipose tissue derived mesenchymal stromal cell; AMSCs, Amniotic derived mesenchymal tissue cells; BMMSCs, Bone marrow derived mesenchymal 
stromal cell; CI, Confidence interval; CM, Conditioned medium; IV, Intravenous; LF, Lung fibrosis; MSCs, Mesenchymal stromal cells; MSCs-CM, Mesenchymal 
stromal cells derived conditioned medium; NA, Not applicable due to one study included in the subgroup; SMD, Standardized mean difference.
than other sources such as AMSCs and BMMSCs. In 
addition, their preparation and autograft transplantation 
are much more practical. Therefore, since the differences 
in cellular source have no effect on the conditioned 
medium’s performance, it is recommended to use ADSCs 
derived conditioned medium in future studies.
In addition, a meta-regression analysis found that, unlike 
many chronic diseases, the interval between the occurrence 
of pulmonary fibrosis and the onset of treatment with 
MSCs-CM did not affect its efficacy. Therefore, it 
seems that even in the chronic phases of the disease, 
this treatment can be used to control the progression of 
pulmonary fibrosis. However, only one study identified a 
4-week gap between the onset of pulmonary fibrosis and 
the onset of MSCs-CM administration. Therefore, the 
efficacy of MSCs-CM administration in the chronic phase 
of pulmonary fibrosis should be further investigated.
After MSCs-CM administration, type I and III collagen 
expression levels decreased significantly. Studies have 
shown that after pulmonary fibrosis, overexpression of 
type I and type III collagen is observed.34,35 These studies 
show that expression of type I collagen is also increased by 
TGF-β1 expression. Therefore, administration of MSCs-
CM seems to modulate collagen expression by reducing 
TGF-β1 expression in lung tissue.
Most of the studies included in the present meta-
analysis used the intravenous route to administer MSCs-
CM. Subgroup analyses also showed that there was no 
difference between intravenous and in situ administration 
of MSCs-CM. This is an advantage for MSCs-CM because 
intravenous administration is one of the simplest routes of 
drug administration, whereas in many cases, intravenous 
administration of MSCs is associated with concern such 
as tumorigenesis.
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In conclusion, the present meta-analysis showed that 
administration of MSCs-CM improved pulmonary 
fibrosis. Since intravenous administration of this 
therapeutic option has fewer risks than MSCs and its 
intravenous administration has a similar efficacy to in situ 
administration, the conditioned medium can be used in 
future studies as an alternative to MSCs transplantation. 
It seems that the effect of MSCs-CM was mediated by 
reducing collagen deposition as well as inhibiting the 
production of inflammatory chemokines such as TGF-β1 
and IL-6. In addition, it appears that ADSCs is the best 
source for preparation of conditioned medium.
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